Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
- 1 September 2013
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Anti-infective Therapy
- Vol. 11 (9), 931-941
- https://doi.org/10.1586/14787210.2013.826989
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009Emerging Infectious Diseases, 2011
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Invasive Aspergillosis in Critically Ill Patients without MalignancyAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Clinical pharmacology of antifungal compoundsInfectious Disease Clinics of North America, 2003
- Aspergillosis: Pathogenesis, clinical manifestations, and therapyInfectious Disease Clinics of North America, 2002
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- Impact of Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of Aminoglycosides on Clinical Outcome: A Cost-Effectiveness AnalysisTherapeutic Drug Monitoring, 1999
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996